Dedicated to a cancer free future
Adecto Pharmaceuticals is a privately-owned, preclinical stage, cancer therapeutics company, founded in 2014 to develop targeted therapies against aggressive ADAM8-positive cancers. It is the culmination of over 30 years of research hunting down molecules that can be safely targeted to stop both primary cancer and metastases.
Our mission is to help patients live longer, healthy lives.
The ADAM8 protein is expressed on the cancer cell surface, downstream of the NF-κB family of transcription factors known to promote tumor growth, resistance to chemotherapy and metastasis. Consistently, ADAM8 is a critical driver of the growth and spread of many aggressive tumor types, including breast, stomach, colon, lung, liver and pancreatic cancers. Adecto’s initial focus is on triple-negative breast cancer with a plan to expand to other oncology indications in the future. It is estimated that globally there are over 2 million patients with invasive ADAM8-driven cancers. Currently, there is no FDA-approved therapy for these patients or a diagnostic assay to identify them. Adecto is developing the first antibody-based therapy against ADAM8-positive cancers and a diagnostic assay to identify those patients most likely to benefit from inhibition of ADAM8.